Form 4 Filing for Aurinia Pharmaceuticals Inc.

On May 18, 2026, Cole Ryan, Chief Operating Officer of Aurinia Pharmaceuticals Inc., acquired 116,144 shares of Common Stock and an Employee Stock Option (right to buy) for 70,230 shares of Common Stock. The Common Stock acquisition was a grant with a transaction price of $0.00 per share. The Employee Stock Option has an exercise price of $15.28 per share and an expiration date of May 18, 2036. The footnotes indicate that the performance stock units (PSUs) vest in tranches based on achieving target stock prices and anniversary dates, with specific vesting schedules outlined. Specifically, 46,820 PSUs vest upon the common shares achieving progressively higher target prices, each with a one-year retention period post-achievement. An additional 69,324 PSUs vest over two years following the three and five-year anniversaries of the grant date, contingent on the common shares reaching target prices significantly higher than the grant date price before their respective vesting dates. The remaining 33% vest on the 1-year anniversary of the grant date, and the subsequent 67% vest in monthly installments over the following two years.